LGND
$210.99
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA an...
Recent News
Assessing Ligand Pharmaceuticals (LGND) Valuation After Bank Of America’s New Buy Rating
Why Ligand Pharmaceuticals is in Focus Right Now Ligand Pharmaceuticals (LGND) is back on investor radars after Bank of America initiated coverage, pointing to the company’s royalty centered business model and broad portfolio of partnered drug programs as key themes to watch. See our latest analysis for Ligand Pharmaceuticals. Bank of America’s upbeat coverage comes as Ligand’s share price sits at US$211.48, with a 30 day share price return of 13.08% and a 1 year total shareholder return of...
How A Broad Sell-Off Rattled Top 3% Breakout Stock Ligand Pharma
Shares of Ligand Pharmaceuticals dropped into a sell zone Thursday, seemingly down in sympathy with the broader biotech segment.
These Are The 5 Best Stocks To Buy Or Watch Now
Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are five top-performing stocks to buy now or put on a watchlist.
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, citing the company’s royalty-focused business model and diversified portfolio as key drivers of continued earnings growth. Ligand provides capital and technology to...
Oracle, Nike upgraded: Wall Street's top analyst calls
Oracle, Nike upgraded: Wall Street's top analyst calls